SCHEMBL15432502

SCHEMBL15432502

CC(=O)c1cccc(C(=O)Nc2ccc(N3CCCCC3)cc2-c2cc(C(=O)NCc3cccc(C(F)(F)F)c3)ccn2)c1

nearest known ligand 0.52

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
SLC34A2 O95436 1/20 0.52
BRAF P15056 4/20 0.48
RAF1 P04049 2/20 0.48
MEN1 O00255 1/20 0.43
KMT2A Q03164 1/20 0.43
ROCK2 O75116 3/20 0.42
ROCK1 Q13464 2/20 0.42
KDM4E B2RXH2 2/20 0.42
HRH4 Q9H3N8 1/20 0.42
MET P08581 1/20 0.42
KCNH2 Q12809 1/20 0.42
KDR P35968 1/20 0.42
SRPK2 P78362 1/20 0.42
SRPK1 Q96SB4 1/20 0.42
SRPK3 Q9UPE1 1/20 0.42
MLYCD O95822 1/20 0.41
CHRM3 P20309 1/20 0.41
TEK Q02763 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL39860 0.93 SLC34A2 (0.53) SLC34A2BRAFRAF1MEN1KMT2A
SCHEMBL39979 0.93 SLC34A2 (0.53) SLC34A2BRAFRAF1ROCK2ROCK1
SCHEMBL40075 0.93 SLC34A2 (0.52) SLC34A2BRAFRAF1ROCK2ROCK1
SCHEMBL16355250 0.93 SLC34A2 (0.51) SLC34A2BRAFRAF1ROCK2ROCK1
SCHEMBL18471336 0.92 SLC34A2 (0.49) SLC34A2BRAFRAF1MEN1KMT2A
SCHEMBL6000691 0.92 SLC34A2 (0.49) SLC34A2BRAFRAF1MEN1KMT2A
SCHEMBL46515 0.91 SLC34A2 (0.51) SLC34A2BRAFRAF1MEN1KMT2A
SCHEMBL39714 0.91 SLC34A2 (0.51) SLC34A2BRAFRAF1MEN1KMT2A
SCHEMBL39843 0.91 SLC34A2 (0.51) SLC34A2BRAFRAF1MEN1KMT2A
SCHEMBL45213 0.91 SLC34A2 (0.48) SLC34A2BRAFRAF1ROCK2ROCK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170037010-A1 COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT ARDELYX, INC. 2017-02-09 US disclosed
US-9301951-B2 Compounds and methods for inhibiting phosphate transport ARDELYX, INC. (US) 2016-04-05 US disclosed
US-20150164876-A1 COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT ARDELYX, INC. 2015-06-18 US disclosed
US-8916569-B2 Compounds and methods for inhibiting phosphate transport ARDELYX, INC. (US) 2014-12-23 US disclosed
US-20140023611-A1 COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT ARDELYX, INC. 2014-01-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150164876-A1 COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT SLC34A2, SLC34A1, SLC10A2 SLC34A2 1/4885BRAF 3436/4885RAF1 3203/4885
US-20170037010-A1 COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT SLC34A2, SLC34A1, SLC10A2 SLC34A2 1/4885BRAF 3436/4885RAF1 3203/4885
US-20140023611-A1 COMPOUNDS AND METHODS FOR INHIBITING PHOSPHATE TRANSPORT SLC10A2, SLC34A2, SLC34A3 SLC34A2 2/4885BRAF 3909/4885RAF1 3987/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.